458 related articles for article (PubMed ID: 10926350)
1. Drug interactions with cisapride: clinical implications.
Michalets EL; Williams CR
Clin Pharmacokinet; 2000 Jul; 39(1):49-75. PubMed ID: 10926350
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Dresser GK; Spence JD; Bailey DG
Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
[TBL] [Abstract][Full Text] [Related]
3. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
4. Torsade de pointes induced by cisapride/clarithromycin interaction.
Piquette RK
Ann Pharmacother; 1999 Jan; 33(1):22-6. PubMed ID: 9972380
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of the QT interval related to cisapride-diltiazem interaction.
Thomas AR; Chan LN; Bauman JL; Olopade CO
Pharmacotherapy; 1998; 18(2):381-5. PubMed ID: 9545159
[TBL] [Abstract][Full Text] [Related]
6. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.
Kivistö KT; Lilja JJ; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Nov; 66(5):448-53. PubMed ID: 10579471
[TBL] [Abstract][Full Text] [Related]
7. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.
Klotz U
Arzneimittelforschung; 2002; 52(3):155-61. PubMed ID: 11963641
[TBL] [Abstract][Full Text] [Related]
8. [Cisapride and risk of cardiac complications].
Cataldo F
Minerva Pediatr; 1999; 51(9-10):309-11. PubMed ID: 10783591
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
10. The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
Vandenplas Y; Belli DC; Benatar A; Cadranel S; Cucchiara S; Dupont C; Gottrand F; Hassall E; Heymans HS; Kearns G; Kneepkens CM; Koletzko S; Milla P; Polanco I; Staiano AM
J Pediatr Gastroenterol Nutr; 1999 May; 28(5):518-28. PubMed ID: 10328131
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers.
Alderman J
Clin Ther; 2005 Jul; 27(7):1050-63. PubMed ID: 16154484
[TBL] [Abstract][Full Text] [Related]
12. Review article: cardiac adverse effects of gastrointestinal prokinetics.
Tonini M; De Ponti F; Di Nucci A; Crema F
Aliment Pharmacol Ther; 1999 Dec; 13(12):1585-91. PubMed ID: 10594392
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
14. [The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe?].
Pelov R; Tankova L; Krushkov I
Vutr Boles; 1999; 31(2-3):5-9. PubMed ID: 10847134
[TBL] [Abstract][Full Text] [Related]
15. Study of the drug-drug interaction between simvastatin and cisapride in man.
Simard C; O'Hara GE; Prévost J; Guilbaud R; Masseé R; Turgeon J
Eur J Clin Pharmacol; 2001 Jun; 57(3):229-34. PubMed ID: 11497338
[TBL] [Abstract][Full Text] [Related]
16. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.
Bohets H; Lavrijsen K; Hendrickx J; van Houdt J; van Genechten V; Verboven P; Meuldermans W; Heykants J
Br J Pharmacol; 2000 Apr; 129(8):1655-67. PubMed ID: 10780971
[TBL] [Abstract][Full Text] [Related]
17. Prokinetic agents and QT prolongation: a familiar scene with new actors.
Keller GA; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):73-8. PubMed ID: 20210722
[TBL] [Abstract][Full Text] [Related]
18. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
van Haarst AD; van 't Klooster GA; van Gerven JM; Schoemaker RC; van Oene JC; Burggraaf J; Coene MC; Cohen AF
Clin Pharmacol Ther; 1998 Nov; 64(5):542-6. PubMed ID: 9834046
[TBL] [Abstract][Full Text] [Related]
19. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN;
Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Sagir A; Schmitt M; Dilger K; Häussinger D
Digestion; 2003; 68(1):41-8. PubMed ID: 12949438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
